These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19166098)

  • 1. ABL1 fusions in T-cell acute lymphoblastic leukemia.
    De Keersmaecker K
    Verh K Acad Geneeskd Belg; 2008; 70(4):245-55. PubMed ID: 19166098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.
    Graux C; Cools J; Melotte C; Quentmeier H; Ferrando A; Levine R; Vermeesch JR; Stul M; Dutta B; Boeckx N; Bosly A; Heimann P; Uyttebroeck A; Mentens N; Somers R; MacLeod RA; Drexler HG; Look AT; Gilliland DG; Michaux L; Vandenberghe P; Wlodarska I; Marynen P; Hagemeijer A
    Nat Genet; 2004 Oct; 36(10):1084-9. PubMed ID: 15361874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABL1 rearrangements in T-cell acute lymphoblastic leukemia.
    Hagemeijer A; Graux C
    Genes Chromosomes Cancer; 2010 Apr; 49(4):299-308. PubMed ID: 20073070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
    De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
    Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
    De Keersmaecker K; Versele M; Cools J; Superti-Furga G; Hantschel O
    Leukemia; 2008 Dec; 22(12):2208-16. PubMed ID: 18784740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore.
    De Keersmaecker K; Rocnik JL; Bernad R; Lee BH; Leeman D; Gielen O; Verachtert H; Folens C; Munck S; Marynen P; Fornerod M; Gilliland DG; Cools J
    Mol Cell; 2008 Jul; 31(1):134-42. PubMed ID: 18614052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
    De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
    Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
    Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
    Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
    Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
    Sindt A; Deau B; Brahim W; Staal A; Visanica S; Villarese P; Rault JP; Macintyre E; Delabesse E
    Genes Chromosomes Cancer; 2006 Jun; 45(6):575-82. PubMed ID: 16518848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.
    Baeumler J; Szuhai K; Falkenburg JH; van Schie ML; Ottmann OG; Nijmeijer BA
    Cancer Genet Cytogenet; 2008 Aug; 185(1):37-42. PubMed ID: 18656692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NUP214-ABL1 in adult T-ALL: the GMALL study group experience.
    Burmeister T; Gökbuget N; Reinhardt R; Rieder H; Hoelzer D; Schwartz S
    Blood; 2006 Nov; 108(10):3556-9. PubMed ID: 16873673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
    Quintás-Cardama A; Tong W; Manshouri T; Vega F; Lennon PA; Cools J; Gilliland DG; Lee F; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2008 Jun; 22(6):1117-24. PubMed ID: 18401417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABL1 fusion genes in hematological malignancies: a review.
    De Braekeleer E; Douet-Guilbert N; Rowe D; Bown N; Morel F; Berthou C; Férec C; De Braekeleer M
    Eur J Haematol; 2011 May; 86(5):361-71. PubMed ID: 21435002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia.
    De Keersmaecker K; Lahortiga I; Graux C; Marynen P; Maertens J; Cools J; Vandenberghe P
    Leukemia; 2006 Dec; 20(12):2202-4. PubMed ID: 17024111
    [No Abstract]   [Full Text] [Related]  

  • 16. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.
    Graux C; Stevens-Kroef M; Lafage M; Dastugue N; Harrison CJ; Mugneret F; Bahloula K; Struski S; Grégoire MJ; Nadal N; Lippert E; Taviaux S; Simons A; Kuiper RP; Moorman AV; Barber K; Bosly A; Michaux L; Vandenberghe P; Lahortiga I; De Keersmaecker K; Wlodarska I; Cools J; Hagemeijer A; Poirel HA; ;
    Leukemia; 2009 Jan; 23(1):125-33. PubMed ID: 18923437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.
    De Keersmaecker K; Porcu M; Cox L; Girardi T; Vandepoel R; de Beeck JO; Gielen O; Mentens N; Bennett KL; Hantschel O
    Haematologica; 2014 Jan; 99(1):85-93. PubMed ID: 23872305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse.
    Clarke S; O'Reilly J; Romeo G; Cooney J
    Leuk Res; 2011 Jul; 35(7):e131-3. PubMed ID: 21489623
    [No Abstract]   [Full Text] [Related]  

  • 19. ABL1 amplification in T-cell acute lymphoblastic leukemia.
    Bernasconi P; Calatroni S; Giardini I; Inzoli A; Castagnola C; Cavigliano PM; Rocca B; Boni M; Quarna J; Zappatore R; Caresana M; Bianchessi C; Pallavicini EB; Lazzarino M
    Cancer Genet Cytogenet; 2005 Oct; 162(2):146-50. PubMed ID: 16213363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of genes differentially regulated by the P210 BCR/ABL1 fusion oncogene using cDNA microarrays.
    Håkansson P; Segal D; Lassen C; Gullberg U; Morse HC; Fioretos T; Meltzer PS
    Exp Hematol; 2004 May; 32(5):476-82. PubMed ID: 15145216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.